GMED Quote, Financials, Valuation and Earnings

Enovis has a net margin of 12.62% compared to Globus Medical's net margin of -10.02%. Globus Medical's return on equity of 4.59% beat Enovis's return on equity of -26.77%.

Globus Medical has a consensus price target of $85.91, signalling upside risk potential of 51.76%. On the other hand Enovis has an analysts' consensus of $56.30 which suggests that it could grow by 84.35%. Given that Enovis has higher upside potential than Globus Medical, analysts believe Enovis is more attractive than Globus Medical.

Globus Medical has a beta of 1.193, which suggesting that the stock is 19.307% more volatile than S&P 500. In comparison Enovis has a beta of 1.494, suggesting its more volatile than the S&P 500 by 49.355%.

Globus Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Enovis offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Globus Medical pays -- of its earnings as a dividend. Enovis pays out -- of its earnings as a dividend.

Globus Medical quarterly revenues are $598.1M, which are larger than Enovis quarterly revenues of $558.8M. Globus Medical's net income of $75.5M is higher than Enovis's net income of -$56M. Notably, Globus Medical's price-to-earnings ratio is 42.25x while Enovis's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Globus Medical is 3.13x versus 0.79x for Enovis. Usually stocks with elevated PS ratios are considered overvalued.

Intuitive Surgical has a net margin of 12.62% compared to Globus Medical's net margin of 30.99%. Globus Medical's return on equity of 4.59% beat Intuitive Surgical's return on equity of 15.82%.

Globus Medical has a consensus price target of $85.91, signalling upside risk potential of 51.76%. On the other hand Intuitive Surgical has an analysts' consensus of $581.45 which suggests that it could grow by 13.42%. Given that Globus Medical has higher upside potential than Intuitive Surgical, analysts believe Globus Medical is more attractive than Intuitive Surgical.

Globus Medical has a beta of 1.193, which suggesting that the stock is 19.307% more volatile than S&P 500. In comparison Intuitive Surgical has a beta of 1.642, suggesting its more volatile than the S&P 500 by 64.249%.

Globus Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Intuitive Surgical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Globus Medical pays -- of its earnings as a dividend. Intuitive Surgical pays out -- of its earnings as a dividend.

Globus Medical quarterly revenues are $598.1M, which are smaller than Intuitive Surgical quarterly revenues of $2.3B. Globus Medical's net income of $75.5M is lower than Intuitive Surgical's net income of $698.4M. Notably, Globus Medical's price-to-earnings ratio is 42.25x while Intuitive Surgical's PE ratio is 75.17x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Globus Medical is 3.13x versus 21.35x for Intuitive Surgical. Usually stocks with elevated PS ratios are considered overvalued.

Insulet has a net margin of 12.62% compared to Globus Medical's net margin of 6.22%. Globus Medical's return on equity of 4.59% beat Insulet's return on equity of 36.9%.

Globus Medical has a consensus price target of $85.91, signalling upside risk potential of 51.76%. On the other hand Insulet has an analysts' consensus of $336.85 which suggests that it could grow by 16.85%. Given that Globus Medical has higher upside potential than Insulet, analysts believe Globus Medical is more attractive than Insulet.

Globus Medical has a beta of 1.193, which suggesting that the stock is 19.307% more volatile than S&P 500. In comparison Insulet has a beta of 1.346, suggesting its more volatile than the S&P 500 by 34.619%.

Globus Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insulet offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Globus Medical pays -- of its earnings as a dividend. Insulet pays out -- of its earnings as a dividend.

Globus Medical quarterly revenues are $598.1M, which are larger than Insulet quarterly revenues of $569M. Globus Medical's net income of $75.5M is higher than Insulet's net income of $35.4M. Notably, Globus Medical's price-to-earnings ratio is 42.25x while Insulet's PE ratio is 51.85x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Globus Medical is 3.13x versus 9.70x for Insulet. Usually stocks with elevated PS ratios are considered overvalued.

RxSight has a net margin of 12.62% compared to Globus Medical's net margin of -21.61%. Globus Medical's return on equity of 4.59% beat RxSight's return on equity of -10.39%.

Globus Medical has a consensus price target of $85.91, signalling upside risk potential of 51.76%. On the other hand RxSight has an analysts' consensus of $12.22 which suggests that it could grow by 67.89%. Given that RxSight has higher upside potential than Globus Medical, analysts believe RxSight is more attractive than Globus Medical.

Globus Medical has a beta of 1.193, which suggesting that the stock is 19.307% more volatile than S&P 500. In comparison RxSight has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Globus Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. RxSight offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Globus Medical pays -- of its earnings as a dividend. RxSight pays out -- of its earnings as a dividend.

Globus Medical quarterly revenues are $598.1M, which are larger than RxSight quarterly revenues of $37.9M. Globus Medical's net income of $75.5M is higher than RxSight's net income of -$8.2M. Notably, Globus Medical's price-to-earnings ratio is 42.25x while RxSight's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Globus Medical is 3.13x versus 1.95x for RxSight. Usually stocks with elevated PS ratios are considered overvalued.